



## Company Overview

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

## Defining Next-Generation Allogeneic CAR T Development

### Pursuing a Differentiated Strategy for CAR Ts



All-in-One vector approach  
Proprietary allogeneic technologies  
shRNA – short hairpin RNA  
shARC – shRNA Armored CAR franchise  
TIM – TCR Inhibitory Molecule

### shRNA-Powered Allogeneic Technology



Non-gene edited shRNA platform offers dynamic technology for the potential development of allogeneic CAR Ts  
Able to multiplex by simultaneously knocking down multiple gene targets of interest  
Currently being evaluated in multiple clinical trials and discovery programs

### Robust Intellectual Property Estate



Twelve foundational U.S. patents associated with allogeneic CAR T for the treatment of cancer  
Strong IP for NKG2D receptor-based cell therapies

## A Differentiated Pipeline of Next Generation CAR T Candidates

### Allogeneic

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	NEXT MILESTONES
CYAD-211	BCMA	r/r MM				<ul style="list-style-type: none"> <li>Additional clinical data expected H2:2022</li> </ul>
CYAD-101	NKG2DL	mCRC				<ul style="list-style-type: none"> <li>Update on CYAD-101-002 trial*</li> </ul>
DISCOVERY PROGRAMS						

### Autologous

	TARGET	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	NEXT MILESTONES
CYAD-02	NKG2DL	r/r AML / MDS				<ul style="list-style-type: none"> <li>Potential partnership opportunity</li> </ul>

# Company Financial Overview



## Listed on:

Euronext & Nasdaq  
CYAD

## Market Capitalization:

~ €32,6 M

## Cash Balance\*:

€ 14.4 million

\*(all figures reported as of August 5, 2022)

## Executive Committee



**Michel Lussier**  
Interim CEO



**Charles Morris**  
CMO



**Philippe Dechamps**  
CLO



**Philippe Nobels**  
VP Human Resources



**An Phan**  
Head of Legal



**Eytan Breman**  
Director of R&D



**Hannes Iserentant**  
Head of IP



**David Georges**  
VP of Finance and Administration



**Thomas Leguettier**  
Head of Cell Therapy Manufacturing Unit

## Upcoming Milestones

### ❑ CYAD-211 in r/r MM

*Enrollment in the cohorts evaluating enhanced lymphodepletion is ongoing in the CYAD-211 IMMUNICY-1 trial and additional data from the trial are expected in the second half of 2022*

## Partnerships

Since its incorporation, Celyad Oncology has built strong partnerships with key international academic institutions and strategic organizations in order to maximize the therapeutic potential of its product candidates and intellectual property.

### Our Partners:

- Celdara Medical
- Dartmouth College
- Horizon Discovery
- MSD
- Novartis
- Walloon Region of Belgium



## Locations

### Headquarters:

Axis Business Park  
Rue Edouard Belin 2,  
1450 Mont-Saint-Guibert

**Belgium**

World Financial District  
60 Broad Street | Suite 3502  
New York, NY 10004

**USA**



## Contacts

+32 (0) 10 39 41 00  
+1 (857) 990-6900

[info@celyad.com](mailto:info@celyad.com)